Teva Pharmaceutical Industries (TEVA) Accumulated Depreciation & Amortization: 2009-2024
Historic Accumulated Depreciation & Amortization for Teva Pharmaceutical Industries (TEVA) over the last 11 years, with Dec 2024 value amounting to $4.4 billion.
- Teva Pharmaceutical Industries' Accumulated Depreciation & Amortization fell 21.77% to $4.4 billion in Q4 2024 from the same period last year, while for Dec 2024 it was $20.8 billion, marking a year-over-year decrease of 3.17%. This contributed to the annual value of $4.4 billion for FY2024, which is 21.77% down from last year.
- Latest data reveals that Teva Pharmaceutical Industries reported Accumulated Depreciation & Amortization of $4.4 billion as of Q4 2024, which was down 21.77% from $5.6 billion recorded in Q4 2023.
- Over the past 5 years, Teva Pharmaceutical Industries' Accumulated Depreciation & Amortization peaked at $5.6 billion during Q4 2023, and registered a low of $4.4 billion during Q4 2024.
- Its 3-year average for Accumulated Depreciation & Amortization is $5.2 billion, with a median of $5.5 billion in 2022.
- As far as peak fluctuations go, Teva Pharmaceutical Industries' Accumulated Depreciation & Amortization grew by 5.29% in 2022, and later decreased by 21.77% in 2024.
- Over the past 5 years, Teva Pharmaceutical Industries' Accumulated Depreciation & Amortization (Quarterly) stood at $5.1 billion in 2020, then rose by 2.93% to $5.2 billion in 2021, then grew by 5.29% to $5.5 billion in 2022, then climbed by 2.16% to $5.6 billion in 2023, then dropped by 21.77% to $4.4 billion in 2024.
- Its last three reported values are $4.4 billion in Q4 2024, $5.6 billion for Q4 2023, and $5.5 billion during Q4 2022.